Corrigenda: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a Phase III study

Michael Millward

doi:10.1093/annonc/mdz221

Corrigenda: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a Phase III study

Michael Millward

Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

31 Citations (Scopus)

Original language	English
Article number	PMID 31406976
Pages (from-to)	1848
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdz221
Publication status	Published - Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz221Licence: CC BY-NC-ND

Cite this

@article{33f8310d5add44b9a82d868d3a843cf5,

title = "Corrigenda: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a Phase III study",

author = "Michael Millward",

year = "2019",

month = nov,

doi = "10.1093/annonc/mdz221",

language = "English",

volume = "30",

pages = "1848",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Corrigenda: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a Phase III study

AU - Millward, Michael

PY - 2019/11

Y1 - 2019/11

U2 - 10.1093/annonc/mdz221

DO - 10.1093/annonc/mdz221

M3 - Comment/debate

C2 - 31406976

SN - 0923-7534

VL - 30

SP - 1848

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

M1 - PMID 31406976

ER -